| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) attributable to parent | -9,246 | - |
| Amortization of deferred financing costs | 18 | - |
| Change in fair value of convertible notes (issued, converted and outstanding) | 0 | - |
| Change in fair value of liability classified warrants (exercised and outstanding) | -32 | -32 |
| Shares issued for the standby equity purchase agreement commitment fee | 298 | - |
| Stock-based compensation | 554 | 264 |
| Change in fair value of convertible notes (issued, converted and outstanding) | - | 0 |
| Accounts receivables, net | 109 | 105 |
| Net loss | - | -5,774 |
| Inventory | 83 | 77 |
| Prepaid expenses | -1,028 | -784 |
| Other assets | -236 | -156 |
| Accounts payable | -1,028 | 112 |
| Shares issued for the standby equity purchase agreement commitment fee | - | 298 |
| Accrued expenses | -1,141 | -1,305 |
| Amortization of deferred financing costs | - | 18 |
| Other liabilities | 0 | 0 |
| Net cash used in operating activities | -9,505 | -5,661 |
| Proceeds from issuance of convertible notes | 0 | 0 |
| Payment of convertible notes | 0 | 0 |
| Proceeds from exercise of warrants | - | 2 |
| Proceeds from issuance of shares, net of offering costs | 14,337 | 5,154 |
| Proceeds from exercise warrants-Convertible Note Warrants | 1,818 | - |
| Proceeds of pre-funded warrants | 5,886 | 5,580 |
| Payment of notes payable | 592 | 592 |
| Net cash provided by financing activities | 21,449 | 10,144 |
| Net increase in cash | 11,944 | - |
| Cash and cash equivalents at beginning of period | 1,819 | - |
| Net increase in cash | - | 4,483 |
| Cash and cash equivalents at end of period | 13,763 | - |
SeaStar Medical Holding Corp (ICUCW)
SeaStar Medical Holding Corp (ICUCW)